Case Name: Monsanto Technology Llc vs Nuziveedu Seeds Ltd. Thru The Director

Citation: Monsanto Technology LLC v. Nuziveedu Seeds Ltd., (2019) 3 SCC 381 (S.C. 2019).

Court: Supreme Court

Corum: Justice Navin Sinha, and Justice Rohinton Fali Nariman

Abstract

The Supreme Court in Monsanto Technology LLC v. Nuziveedu Seeds Ltd. addressed whether a patented nucleic acid sequence that is inserted into a plant would remain excluded from patentability under Section 3(j) of the Patents Act, or whether it may warrant protection under the PPVFR Act. The Supreme Court then declined to resolve this question and held that it required trial-based technical evidence rather than a summary determination. The court further set aside the revocation of Monsanto’s patent made by the Division Bench, and ruled that the interlocutory proceedings could not decide the complex patentability disputes without necessary pleadings and evidence. This judgment offers a procedural clarity and had left the doctrinal overlap between patent and plant-variety regimes unresolved for any future adjudication.

Introduction

This judgment raises a critical controversy at the intersection of patent law and plant-variety protection that can a patented genetically engineered nucleic acid sequence that is once inserted into a plant cannot then be excluded from patentability under section 3(j) of the Patents Act in favour of protection under PPVFR Act and can this question be decided summarily. This has arisen in the agro-biotechnology sector concerning Bt cotton seed technology and has helped develop an understanding by the Supreme Court on gene-technology patents and if it can get defeated by plant-variety exclusion. 

Facts

Monsanto, a holder of Patent No. 214436, in 2004 entered in a ten-year sub-license agreement with Nuziveedu Seeds and had permitted the latter to develop and commercially exploit “Bollgard”/”Bollgard II” Bt cotton hybrid seeds with the use of Monsanto’s patented technology, in exchange for periodic licence fees (“trait value”).   Monsanto, in 2015, terminated the agreement due to disputes over fee revisions, which was triggered by a subsequent state price-control regime. Monsanto sued for injunction and infringement, which prompted Nuziveedu to counter-claim the revocation under Section 64, and contended that the claims 1-24(process) and 25-27(NAS/product) were unpatentable under section 3(j), being either “essentially biological processes” or plants/plant parts, and they were protectable only under PPVFR Act. The Single Judge in 2017 had granted a limited injunction and preserved the status quo on fee payment. The Division Bench went further and examined the unargued counter-claim and held all the claims as unpatentable under Section 3(j), and treated the Patents Act and PPVFR Act as mutually exclusive regimes.

Issues

1.     Whether a patented nucleic acid sequence which is inserted into a plant cell is excluded from the patentability under section 3(j) of the Patents Act or whether it can be validly protected alongside the PPVFR Act?

2.     Whether the issues of patentability and revocation could be decided by the Division Bench at the interlocutory stage without having a full trial, pleadings, and expert evidence?

Reasoning

On issue 1:
The court had declined to determine whether NAS would fall within section 3(j) exclusion, and treated this as a complex mixed question of law and fact rather than one that is capable of an abstract resolution. The court then determined whether a gene sequence that is once inserted into a plant cell, would constitute constitutes a “plant,” “seed,” or product of an “essentially biological process”, and whether it is registrable under the PPVFR Act would require technical evidence on biochemistry, genetics, and microbiology. The Court further left open the question of whether the Patents Act and PPVFR Act operate exclusively or complementarily, refusing to pronounce on patentability and reserving the question for trial on full evidence.

On issue 2:
The Court held that the Division Bench had exceeded the scope of an interlocutory injunction appeal by deciding on Nuziveedu’s counter-claim for revocation that had only reached the stage of “notice issued” before the Single Judge and it was never argued or adjudicated on merits. The Court then relied on Alka Gupta v. Narender Kumar Gupta and emphasized that civil suits must not be decided by relying on public-domain documents that had never exhibited in the suit and it must be decided only through pleadings, framed issues, and evidence that is tested by cross-examination. The court then held that summary revocation of a subsisting patent was without trial impermissible and the Single Judge’s order was restored and accordingly the suit was remanded.

Post-remand Status

The issues of patentability and infringement were kept open when on remand, the suit was returned to the Single Judge Bench for trial. By November 2019, Patent No. 214436 had lapsed on expiry, which reduced Monsanto’s claim to damages that are contingent on the NAS being held patentable. No reported final adjudication on the Section 3(j)/PPVFR question has since emerged, and the suit since then has appeared to remain pending, which means that the doctrinal question which has been flagged here would still have to await determination.

Critique

The Supreme Court in this judgment was completely right to flag the doubtful fit between a gene/DNA construct and the definition of plant variety” under Section 2(za) of the PPVFR Act, that contemplates a “plant grouping” within a single botanical taxon, a category of molecular construct that does not intuitively occupy. The glossing made by the Division Bench over this mismatch while asserting mutual exclusivity between the two statutes was analytically thin, yet the Supreme Court had left unresolved the tension that every seed company and PPVFR- registered breeder confronts which is whether a patented trait that is embedded within a PPVFR-registered variety can be enforced against while exercising the rights of re-sowing under section 39. This avoidance carries a real economic cost, raising the litigation-risk premium on GM-trait licensing and inviting delayed entry or a shift toward jurisdictions with clearer patent/plant-variety demarcation. This essentially results in a “process win, substance deferred” judgment, that is procedurally correct but leaves the core patent-versus-plant variety interface as unsettled as before.

Impact

For the PPVFR stakeholders, this judgment leaves unresolved whether the providers of GM traits must have registered under the PPVFR Act instead of, or alongside, patenting, which perpetuates uncertainty for hybrid seed companies that license Bt/GM technology. For the breeders and farmers, the continuation of trait-fee obligations under the statutory price-control regime, even mid-litigation, signals judicial sensitivity to farmer welfare and concerns of affordability. For the patent strategy in agri-biotech, this judgment helps strengthen the patentees procedurally by establishing that the courts cannot summarily invalidate the patents at the interlocutory stage in infringement suits, even while section 3(j)/PPVFR overlap question open for litigation.

Conclusion

This judgment leaves the deeper doctrinal question of patent-PPVFR overlap open but represents a procedural victory for Monsanto. The Supreme Court’s restraint leaves unanswered the question of whether a gene or DNA construct be classified as a “plant variety”. The real resolution of this tension between the agri-biotech patenting and plant-variety protection awaits a determination at a trial, or a Supreme Court Bench that confronts this substantive issue in the future.

References

Monsanto Technology LLC v. Nuziveedu Seeds Ltd. (2019) 3 SCC 381

Alka Gupta v. Narender Kumar Gupta (2010) 10 SCC 141

The Patents Act, 1970

The Patents (Amendment) Act, 2002

Protection of Plant Varieties and Farmers’ Rights Act, 2001